Your browser doesn't support javascript.
loading
Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates.
Otsuka, Yukio; Poondru, Srinivasu; Bonate, Peter L; Rose, Rachel H; Jamei, Masoud; Ushigome, Fumihiko; Minematsu, Tsuyoshi.
Afiliação
  • Otsuka Y; Clinical Pharmacology and Exploratory Development, Astellas Pharma Inc., 2-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, 103-8411, Japan. yukio.otsuka@astellas.com.
  • Poondru S; Clinical Pharmacology and Exploratory Development, Astellas Pharma Global Development Inc., Northbrook, IL, USA.
  • Bonate PL; Clinical Pharmacology and Exploratory Development, Astellas Pharma Global Development Inc., Northbrook, IL, USA.
  • Rose RH; Simcyp Division, Certara UK, Sheffield, UK.
  • Jamei M; Simcyp Division, Certara UK, Sheffield, UK.
  • Ushigome F; Applied Research and Operations, Astellas Pharma Inc., Ibaraki, Japan.
  • Minematsu T; Immuno-oncology, Astellas Pharma Inc., Ibaraki, Japan.
J Pharmacokinet Pharmacodyn ; 50(5): 365-376, 2023 10.
Article em En | MEDLINE | ID: mdl-37344637
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Citocromo P-450 CYP3A / Rivaroxabana Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: J Pharmacokinet Pharmacodyn Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Citocromo P-450 CYP3A / Rivaroxabana Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: J Pharmacokinet Pharmacodyn Ano de publicação: 2023 Tipo de documento: Article